Segregation and potential functional impact of a rare stop-gain PABPC4L variant in familial atypical Parkinsonism

Muhammad Aslam, Anwar Ullah, Nagarajan Paramasivam, Nirosiya Kandasamy, Saima Naureen, Mazhar Badshah, Kafaitullah Khan, Muhammad Wajid, Rashda Abbasi, Roland Eils, Marc A. Brockmann, Matthias Schlesner, Nafees Ahmad, Jakob von EngelhardtScientific 2019 · DOI

Introduction

Atypical parkinsonian disorders (APDs) represent a heterogeneous group of neurodegenerative diseases that share clinical features with Parkinson’s disease but often exhibit more rapid progression and a poor response to dopaminergic therapies. While most APD cases are sporadic, rare familial forms offer critical insights into the underlying molecular mechanisms of neurodegeneration. Recent research has highlighted the role of ribonucleic acid (RNA) stress granule (SG) pathways in various neurodegenerative conditions. This study investigates a family with a history of APD to identify the genetic basis and functional consequences of a novel candidate variant.

Genetic Identification and Co-segregation

Using whole-genome sequencing (WGS) on a family with six members exhibiting symptoms of atypical parkinsonism—including ataxia and brainstem/cerebellar atrophy—researchers identified a heterozygous stop-gain variant (c.C811T; p.R271X) in the PABPC4L (Poly(A) binding protein, cytoplasmic 4-like) gene.

Pedigree of the family showing co-segregation of the PABPC4L p.R271X variant with the disease phenotype.

The variant co-segregated perfectly with the disease phenotype across two generations. Bioinformatics analysis using the CADD (Combined Annotation Dependent Depletion) tool ranked this substitution in the top 0.1% of deleterious variants, with a score of 38. The filtering process narrowed down millions of variants to this specific candidate.

Flowchart illustrating the variant filtering strategy from whole-genome sequencing data.

Clinical and Anatomical Correlation

Affected family members displayed clinical symptoms consistent with APD, and magnetic resonance imaging (MRI) revealed significant atrophy in the brainstem and cerebellum. To determine if PABPC4L expression aligned with these clinical findings, the team analyzed human microarray data and performed in situ hybridization in mice. The results confirmed high expression of PABPC4L in the cerebellum and brainstem, providing an anatomical link between the gene's function and the observed pathology.

Functional Impact of the p.R271X Variant

The identified mutation is a "stop-gain" variant that results in a truncated protein lacking the C-terminal RRM4 motif. Functional assays in HEK293 cells revealed that while wild-type PABPC4L is primarily a nuclear protein, the truncated p.R271X version is distributed homogeneously throughout the cell.

Crucially, the study examined the protein's behavior under oxidative stress. In response to sodium arsenite treatment, wild-type PABPC4L successfully relocated to cytoplasmic stress granules labeled with G3BP. In contrast, the truncated protein failed to associate with these granules. This suggests that the mutation impairs the protein's ability to participate in the cellular stress response, potentially leaving neurons vulnerable to oxidative damage.

Conclusion

This study provides genetic and molecular evidence for the role of a rare PABPC4L stop-gain variant in familial atypical parkinsonism. The findings suggest that the disease may be driven by cellular mislocalization and the failure of the protein to integrate into protective stress granules. While these results were obtained in heterologous cell models, they open new avenues for investigating RNA metabolism and stress response pathways in the pathogenesis of APDs. Future research using patient-derived neurons will be essential to further validate these mechanisms.

Summary updated

Abstract

Atypical parkinsonian disorders (APDs) comprise a group of neurodegenerative diseases with heterogeneous clinical and pathological features. Most APDs are sporadic, but rare familial forms have also been reported. Epidemiological and post-mortem studies associated APDs with oxidative stress and cellular protein aggregates. Identifying molecular mechanisms that translate stress into toxic protein aggregation and neurodegeneration in APDs is an active area of research. Recently, ribonucleic acid (RNA) stress granule (SG) pathways were discussed to be pathogenically relevant in several neurodegenerative disorders including APDs. Using whole genome sequencing, mRNA expression analysis, transfection assays and cell imaging, we investigated the genetic and molecular basis of a familial neurodegenerative atypical parkinsonian disorder. We investigated a family with six living members in two generations exhibiting clinical symptoms consistent with atypical parkinsonism. Two affected family members suffered from parkinsonism that was associated with ataxia. Magnetic resonance imaging (MRI) of these patients showed brainstem and cerebellar atrophy. Whole genome sequencing identified a heterozygous stop-gain variant (c.C811T; p.R271X) in the Poly(A) binding protein, cytoplasmic 4-like (PABPC4L) gene, which co-segregated with the disease in the family. In situ hybridization showed that the murine pabpc4l is expressed in several brain regions and in particular in the cerebellum and brainstem. To determine the functional impact of the stop-gain variant in the PABPC4L gene, we investigated the subcellular localization of PABPC4L in heterologous cells. Wild-type PABPC4L protein localized predominantly to the cell nucleus, in contrast to the truncated protein encoded by the stop-gain variant p.R271X, which was found homogeneously throughout the cell. Interestingly, the wild-type, but not the truncated protein localized to RasGAP SH3 domain Binding Protein (G3BP)-labeled cytoplasmic granules in response to oxidative stress induction. This suggests that the PABPC4L variant alters intracellular distribution and possibly the stress granule associated function of the protein, which may underlie APD in this family. In conclusion, we present genetic and molecular evidence supporting the role of a stop-gain PABPC4L variant in a rare familial APD. Our data shows that the variant results in cellular mislocalization and inability of the protein to associate with stress granules.
BibTeX
@inproceedings{aslam2019segregation,
  author = {Muhammad Aslam and Anwar Ullah and Nagarajan Paramasivam and Nirosiya Kandasamy and Saima Naureen and Mazhar Badshah and Kafaitullah Khan and Muhammad Wajid and Rashda Abbasi and Roland Eils and Marc A. Brockmann and Matthias Schlesner and Nafees Ahmad and Jakob von Engelhardt},
  title = {{Segregation and potential functional impact of a rare stop-gain PABPC4L variant in familial atypical Parkinsonism}},
  booktitle = {Scientific},
  year = {2019},
  doi = {10.1038/s41598-019-50102-6},
}
Figure